miR-101 regulates cell proliferation and apoptosis by targeting KDM1A in diffuse large B cell lymphoma

Figures & data

Figure 1 miR-101 had reduced expression levels in DLBCL.

Notes: (A) miR-101 expression levels were measured in DLBCL and normal lymph node tissues by qRT-PCR. *Compared with NC, P<0.001. (B) miR-101 expression levels were measured in DLBCL cell lines by qRT-PCR. *Compared with NC, P<0.001.

Abbreviations: DLBCL, diffuse large B cell lymphoma; NC, normal control.

Table 1 The correlation between miR-101 expression and clinicopathological features was analyzed in DLBCL

Clinicopathological features	N	miR-101		P-value
		High-expression	Low-expression
Age (years)				0.458
≤58	12	6	6
>58	18	6	12
Gender				0.442
Male	19	9	10
Female	11	3	8
Extra-nodal status
<2	5	4	1	0.128
≥2	25	8	17
B symptoms
Absent	10	5	5	0.461
Present	20	7	13
LDH
<300	13	7	6	0.264
≥300	17	5	12
Clinical stage				0.013
I–II	9	7	2
III–IV	21	5	16
Tumor size (cm)				0.034
≤3	8	6	2
>3	22	6	16
IPI score				0.026
0–2	6	5	1
≥3	24	7	17

Abbreviations: LDH, lactate dehydrogenase; IPI, International Prognostic Index.

Figure 2 miR-101 down-regulation regulated cell apoptosis and proliferation in DLBCL.

Notes: (A) The down-regulation and up-regulation of miR-101 in OCL-LY8 cells were validated by qRT-PCR. *Compared with control, P<0.001. (B) MTT assay revealed that miR-101 regulated cell proliferation. (C) Flow cytometric analysis revealed that miR-101 regulated cell apoptosis.

Figure 3 KDM1A is the target of miR-101.

Notes: (A) KDM1A was the predicted target of miR-101 by TargetScanHuman 7.1. (B) KDM1A was highly expressed in DLBCL tissues compared with those in normal tissues. *Compared with NC, P<0.001. (C) miR-101 negatively regulated the mRNA level of KDM1A. *Compared with control, P<0.001. (D) miR-101 negatively regulated the protein level of KDM1A.

Figure 4 miR-101 negatively regulated KDM1A to affect cell proliferation and apoptosis.

Notes: (A) KDM1A down-regulation didn’t affect the expression of miR-101. *Compared with control, P<0.001. (B) MTT assay shows that KDM1A down-regulation resulted in the inhibition of cell proliferation and partially enhanced the miR-101-induced inhibition of cell proliferation. (C) Flow cytometric analysis revealed that KDM1A down-regulation promoted cell apoptosis and partially enhanced the miR-101-induced promotion of cell apoptosis.

Table 2 The correlation between KDM1A expression and clinicopathological features was analyzed in DLBCL

Clinicopathological features	N	KDM1A		P-value
		High-expression	Low-expression
Age (years)				0.139
≤58	12	6	6
>58	18	14	4
Gender				0.246
Male	19	11	8
Female	11	9	2
Tumor size (cm)				0.007
≤3	8	2	6
>3	22	18	4
Stage				0.222
I–II	9	5	5
III–IV	21	16	5
Extra-nodal status				0.002
<2	5	0	5
≥2	25	20	5
B symptoms				0.461
Absent	10	5	5
Present	20	7	13
LDH				0.056
<300 U/L	13	6	7
≥300 U/L	17	14	3
IPI score				0.009
0–2	6	1	5
≥3	24	19	5

Abbreviations: LDH, lactate dehydrogenase; IPI, International Prognostic Index.